Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies
Pulmonary infection is a serious public health challenge with high morbidity and mortality. The employment of antibiotics is the first-line treatment for pulmonary infections, while other novel anti-infection agents, such as antimicrobial peptides, have also been developed due to the emergence of dr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/10717544.2025.2544683 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221998887043072 |
|---|---|
| author | Yihong Gao Wenhao Wang Xiao Yue Guanlin Wang Kaiqing Zhang Chuanbin Wu Ziyu Zhao Zhengwei Huang Xuejuan Zhang |
| author_facet | Yihong Gao Wenhao Wang Xiao Yue Guanlin Wang Kaiqing Zhang Chuanbin Wu Ziyu Zhao Zhengwei Huang Xuejuan Zhang |
| author_sort | Yihong Gao |
| collection | DOAJ |
| description | Pulmonary infection is a serious public health challenge with high morbidity and mortality. The employment of antibiotics is the first-line treatment for pulmonary infections, while other novel anti-infection agents, such as antimicrobial peptides, have also been developed due to the emergence of drug resistance. Recently, inhalable nanoparticle-based delivery systems have garnered significant attention for the delivery of anti-infection agents, which possess great advantages like high lung accumulations and precise delivery performances. However, the respiratory physiological structure, mucus and biofilm have been considered as the barriers that nanoparticle drug delivery systems facing, which compromise the therapeutic effects. In this integrative review, recent advances in the inhalable nanoparticle-based delivery system were introduced. In addition, we focused on the biological characteristics of these barriers and discussed effective strategies to overcome the obstacles, including precise deposition in the lower respiratory tract infection site, effective penetration of mucus and breaking of the biofilm barrier. To sum up, this review aimed to deepen the understanding of the fate of anti-infective nanoformulations in pulmonary delivery and find effective strategies to address the barriers, thus providing new insights for the development of pulmonary delivery systems against pulmonary infections. |
| format | Article |
| id | doaj-art-acf6d5aafc4345f7bc7a9126a121d589 |
| institution | Kabale University |
| issn | 1071-7544 1521-0464 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj-art-acf6d5aafc4345f7bc7a9126a121d5892025-08-26T10:08:16ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642025-12-0132110.1080/10717544.2025.2544683Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategiesYihong Gao0Wenhao Wang1Xiao Yue2Guanlin Wang3Kaiqing Zhang4Chuanbin Wu5Ziyu Zhao6Zhengwei Huang7Xuejuan Zhang8College of Pharmacy, Jinan University, Guangzhou, PR ChinaSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, PR ChinaCollege of Pharmacy, Jinan University, Guangzhou, PR ChinaSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, PR ChinaCollege of Pharmacy, Jinan University, Guangzhou, PR ChinaCollege of Pharmacy, Jinan University, Guangzhou, PR ChinaCollege of Pharmacy, Jinan University, Guangzhou, PR ChinaCollege of Pharmacy, Jinan University, Guangzhou, PR ChinaCollege of Pharmacy, Jinan University, Guangzhou, PR ChinaPulmonary infection is a serious public health challenge with high morbidity and mortality. The employment of antibiotics is the first-line treatment for pulmonary infections, while other novel anti-infection agents, such as antimicrobial peptides, have also been developed due to the emergence of drug resistance. Recently, inhalable nanoparticle-based delivery systems have garnered significant attention for the delivery of anti-infection agents, which possess great advantages like high lung accumulations and precise delivery performances. However, the respiratory physiological structure, mucus and biofilm have been considered as the barriers that nanoparticle drug delivery systems facing, which compromise the therapeutic effects. In this integrative review, recent advances in the inhalable nanoparticle-based delivery system were introduced. In addition, we focused on the biological characteristics of these barriers and discussed effective strategies to overcome the obstacles, including precise deposition in the lower respiratory tract infection site, effective penetration of mucus and breaking of the biofilm barrier. To sum up, this review aimed to deepen the understanding of the fate of anti-infective nanoformulations in pulmonary delivery and find effective strategies to address the barriers, thus providing new insights for the development of pulmonary delivery systems against pulmonary infections.https://www.tandfonline.com/doi/10.1080/10717544.2025.2544683Pulmonary infectionsnanoparticle-based delivery systemphysiological barriermucus barrierbiofilm barrier |
| spellingShingle | Yihong Gao Wenhao Wang Xiao Yue Guanlin Wang Kaiqing Zhang Chuanbin Wu Ziyu Zhao Zhengwei Huang Xuejuan Zhang Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies Drug Delivery Pulmonary infections nanoparticle-based delivery system physiological barrier mucus barrier biofilm barrier |
| title | Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies |
| title_full | Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies |
| title_fullStr | Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies |
| title_full_unstemmed | Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies |
| title_short | Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies |
| title_sort | inhalable nanoparticle based delivery systems for the treatment of pulmonary infections status quo and barrier overcoming strategies |
| topic | Pulmonary infections nanoparticle-based delivery system physiological barrier mucus barrier biofilm barrier |
| url | https://www.tandfonline.com/doi/10.1080/10717544.2025.2544683 |
| work_keys_str_mv | AT yihonggao inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT wenhaowang inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT xiaoyue inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT guanlinwang inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT kaiqingzhang inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT chuanbinwu inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT ziyuzhao inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT zhengweihuang inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies AT xuejuanzhang inhalablenanoparticlebaseddeliverysystemsforthetreatmentofpulmonaryinfectionsstatusquoandbarrierovercomingstrategies |